ArticleFrontiers in pharmacology2024
Large variability in the alkaloid content of
Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Introduction: Extracts from the rhizome of the traditional Chinese medicinal plant Methods: Nineteen alkaloids were quantified using HPLC analyses with diode array detection after extraction using a weak cation exchange column. Results: Total alkaloid content was highly variable among the products, ranging from below quantifiable in some to ≈11 mg/g in others. Five of the products had comparable content of alkaloids (9.5 ± 1.6 mg/g), equaling about the amount of alkaloids of an extract prepared from CY rhizome (12.7 mg/g). The other samples had much lower content (1.8 ± 0.9 mg/g), or alkaloids were below quantifiable. One of the products was highly enriched in tetrahydropalmatine (≈5 mg/g), suggesting adulteration from the natural product, and raising concerns about possible toxicologic liability. Discussion: Considering alkaloid content as a key quality criterium for CY supplements, the large variability among the products seems unacceptable and makes it difficult for consumers to select products with an appropriate content of alkaloids.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.